Clinical logistics · when the scale stalls
The plateau protocol audit: what to check, in order, before anyone changes your dose
A plateau worth acting on is four-plus weeks of stable weight at a stable dose with stable adherence — anything shorter is noise wearing a costume. Before the escalation conversation, run the audit in this order, because each step is cheaper than the next: (1) adherence drift — missed or stretched doses, injection technique, a fridge that wandered out of 36–46°F; (2) behavioral drift — the protein scaffold sagging, liquid calories returning, portions quietly re-inflating (the trial-behavior reread is the checklist); (3) dose headroom — where you actually sit on the titration ladder versus maximum tolerated; then and only then (4) the legitimate escalations: a prescriber-managed dose step, the molecule switch up with its trial-anchored ~6-point average gap, or the reframe nobody markets — that this number might be your maintenance weight, and holding it is a win the withdrawal trials say most people don’t get for free. What’s never on the list: stacking, “boosters,” and forum-dose improvisation. Your prescriber owns every change; this page owns the order of questions.
Defining a real plateau — four weeks, three stables
Weekly weight is a noisy instrument: water, sodium, cycle phase, travel, and a heavy dinner can swing multiple pounds with zero fat-mass meaning. The working definition that keeps people from panicking at static: four consecutive weeks, same-scale same-conditions weigh-ins, within about a two-pound band, at an unchanged dose, with honest adherence. Two of those weeks landing during titration don’t count — the ladder itself creates pause-and-drop rhythms. And a plateau after 15–20% lost reads completely differently than one at month three: the trials’ own curves flatten toward their averages, which means late-course flattening is the medication arriving at its destination, not failing en route. Log four clean weeks before the word “plateau” enters a clinical message; you’ll either save the conversation or arrive at it with data.
The three-drift audit — cheapest fixes first
Adherence drift. Pull your actual injection dates from the calendar you built in the waiting room: stretched intervals (nine-day “weeks”) quietly lower average drug levels; a vial that rode a warm doorstep or a fridge door shelf may have lost potency invisibly — check the thermometer’s story, not your memory of it. Behavioral drift. Appetite suppression fades as a novelty even when it persists as a fact; the audit is a boring three-day food log scored against your 1.2–1.6 g/kg protein target and a liquid-calorie count — the two lines that predict most stalls. Drift here isn’t moral failure; it’s the default trajectory the trial’s behavioral scaffold existed to resist, and re-tightening it un-sticks a meaningful share of “medication plateaus.” Dose headroom. Know your ladder position cold: if you’re at 1.0 mg semaglutide or 7.5 mg tirzepatide, most of the labeled range still sits above you and the conversation is ordinary titration, not crisis; at maximum tolerated, the headroom question is answered and the next section applies. Bring all three audits to the clinical conversation — prescribers escalate faster and smarter for patients who arrive with the homework done.
Legitimate escalations — and the counterfeit ones
Three real doors, one at a time, prescriber’s hand on each: the dose step, if headroom exists and side effects allow — the boring, correct first move. The molecule switch up — semaglutide plateau to tirzepatide is the best-evidenced scenario in the switching file, with the head-to-head’s ~20.2%-versus-13.7% averages setting honest (not guaranteed) expectations; the bridge mechanics and pricing traps are already written. The scaffold rebuild — structured resistance training and a protein-first reset, which reads like a consolation prize and performs like an intervention, particularly for body-composition plateaus where the scale hides recomposition. The counterfeit doors, named so they’re recognizable: compounding-pharmacy “boosters” and additive blends (unstudied combinations wearing clinical costumes), forum-sourced dose jumps (survivorship bias in the wild), and any plan whose first step is a different vial instead of a different conversation.
The maintenance reframe — when the plateau is the destination
The withdrawal literature is blunt: stop the medication and, on average, a large share of lost weight returns within a year — which converts “I’ve stopped losing” into a different sentence: “the medication is currently holding a result most people cannot hold unmedicated.” If your plateau sits at or past the 10–15% range where the metabolic-health dividends concentrate, the audit’s final question isn’t how to lose more; it’s whether this is maintenance — and maintenance has its own playbook (dose, interval, and cost optimizations that belong to the stopping-well file and your prescriber, not to disappointment). Plenty of “plateau problems” dissolve the moment the goalpost is audited as honestly as the adherence was.
FAQ
How long is a real GLP-1 plateau?
Four-plus consecutive weeks within about a two-pound band at a stable dose with honest adherence — shorter windows are usually water, cycle, or measurement noise.
Should I increase my dose if I plateau?
Only after the three-drift audit (adherence, behavior, headroom) and only with your prescriber — many stalls resolve at the audit stage without touching the dose.
Does switching to tirzepatide break a semaglutide plateau?
It’s the best-evidenced escalation — the head-to-head averaged roughly 20.2% vs 13.7% — with individual results varying and the switch mechanics covered in the dedicated playbook.